1-229433067-C-T
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Moderate
The NM_001100.4(ACTA1):c.49G>A(p.Gly17Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G17R) has been classified as Likely pathogenic.
Frequency
Consequence
NM_001100.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ACTA1 | NM_001100.4 | c.49G>A | p.Gly17Ser | missense_variant | 2/7 | ENST00000366684.7 | NP_001091.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ACTA1 | ENST00000366684.7 | c.49G>A | p.Gly17Ser | missense_variant | 2/7 | 1 | NM_001100.4 | ENSP00000355645.3 | ||
ACTA1 | ENST00000366683.4 | c.49G>A | p.Gly17Ser | missense_variant | 2/7 | 5 | ENSP00000355644.4 | |||
ACTA1 | ENST00000684723.1 | c.-6-187G>A | intron_variant | ENSP00000508084.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 38
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Actin accumulation myopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 15, 2019 | This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with serine at codon 17 of the ACTA1 protein (p.Gly17Ser). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and serine. This variant has been observed to be de novo in an individual affected with nemaline myopathy (PMID: 29274205). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Gly17 amino acid residue in ACTA1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10508519, 15226407, 17227580, 20621480, 23294764). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at